Cellectis S.A. Banner Image

Cellectis S.A. has reached its limit for free report views

Work for Cellectis S.A.? Upgrade Your Profile and unlock all your annual reports.

Cellectis S.A.

  • Ticker CLLS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Cellectis S.A. Logo Image
  • 201-500 Employees
  • Based in Paris, France
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR Tcells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALENĀ®, its geneMore editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
4.8 / 5.0 (125)

Cellectis S.A. reports have an aggregate usefulness score of 4.8 based on 125 reviews.

Cellectis S.A.

Most Recent Annual Report

Cellectis S.A.
MOST RECENT 2022 Annual Report

Report Locked. Cellectis S.A. has reached its limit for free report views.

Older/Archived Annual Reports

Cellectis S.A. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!